Inivata Ltd:企業の製品パイプライン分析2018

GlobalDataが発行した調査報告書(DATA904C0451)
◆英語タイトル:Inivata Ltd - Product Pipeline Analysis, 2018 Update
◆商品コード:DATA904C0451
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年7月
◆ページ数:32
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:イギリス
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD1,500 ⇒換算¥222,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD2,250 ⇒換算¥333,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Inivata Ltd (Inivata) is a cancer genomics company. The company offers products such as invisionfirst- lungin and visionseq. Its InVisionFirst offers advanced sequencing technology to detect single nucleotide variants copy number variants, insertions and deletions and structural variants in selected genes from dna isolated from plasma samples from patients with non-small cell lung cancer. Inivata works with industry and academic researchers to develop new clinical applications for liquid biopsy and ctdna analysis. The company offers Liquid biopsies to clinical outcomes. It operates in Canada and the US. Inivata is headquartered in Cambridge, the UK.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Inivata Ltd
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Inivata Ltd Company Overview 5
Inivata Ltd Company Snapshot 5
Inivata Ltd Pipeline Products and Ongoing Clinical Trials Overview 5
Inivata Ltd – Pipeline Analysis Overview 7
Inivata Ltd – Key Facts 7
Inivata Ltd – Major Products and Services 8
Inivata Ltd Pipeline Products by Development Stage 9
Inivata Ltd Ongoing Clinical Trials by Trial Status 10
Inivata Ltd Pipeline Products Overview 12
InVision ctDNA Assay – EGFR-Mutant NSCLC 12
InVision ctDNA Assay – EGFR-Mutant NSCLC Product Overview 12
InVision ctDNA Assay – Metastatic Breast Cancer 13
InVision ctDNA Assay – Metastatic Breast Cancer Product Overview 13
InVision ctDNA Assay – NSCLC 14
InVision ctDNA Assay – NSCLC Product Overview 14
InVision ctDNA Assay – NSCLC Clinical Trial 15
InVision ctDNA Assay – Pancreatic Cancer 16
InVision ctDNA Assay – Pancreatic Cancer Product Overview 16
InVision ctDNA Assay – Stage III/IV NSCLC 17
InVision ctDNA Assay – Stage III/IV NSCLC Product Overview 17
InVision First 18
InVision First Product Overview 18
InVision First Clinical Trial 19
Inivata Ltd – Key Competitors 20
Inivata Ltd – Key Employees 21
Inivata Ltd – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Inivata Ltd, Recent Developments 23
Jun 01, 2018: Addario Lung Cancer Medical Institute Collaborates with Washington University on ctDNA Analysis in Early Stage Lung Cancer Study 23
May 08, 2018: Michael Stocum to step down as Inivata CEO 23
Apr 11, 2018: Presentation of New Data on Inivata’s Industry-Leading Liquid Biopsy Platform at AACR 2018 Annual Meeting 24
Mar 19, 2018: Inivata Publishes Results of Analytical Validation for InVisionFirst-Lung ctDNA Liquid Biopsy 24
Mar 15, 2018: Inivata Announces Collaboration with MedStar Health to Utilize Liquid Biopsy to Advance Precision Cancer Genomics 25
Oct 26, 2017: Inivata Announces World-Leading SAB 25
Oct 17, 2017: Inivata Highlights New Clinical Data on InVision ctDNA Liquid Biopsy Platform in advanced NSCLC at WCLC 2017 26
Oct 17, 2017: Inivata Highlights New Clinical Data on InVision ctDNA Liquid Biopsy Platform in advanced NSCLC at WCLC 2017 27
Oct 13, 2017: Inivata Collaborates with Genomics England to Assess Samples and Explore Potential of Liquid Biopsy to Improve Cancer Management and Patient Outcomes 28
Sep 27, 2017: Addario Lung Cancer Medical Research Institute and Inivata Announce Major Study of ctDNA Analysis in Early Stage Lung Cancer 28
Appendix 29
Methodology 29
About GlobalData 32
Contact Us 32
Disclaimer 32

List of Tables
Inivata Ltd Pipeline Products and Ongoing Clinical Trials Overview 5
Inivata Ltd Pipeline Products by Equipment Type 6
Inivata Ltd Pipeline Products by Indication 6
Inivata Ltd Ongoing Clinical Trials by Trial Status 6
Inivata Ltd, Key Facts 7
Inivata Ltd, Major Products and Services 8
Inivata Ltd Number of Pipeline Products by Development Stage 9
Inivata Ltd Pipeline Products Summary by Development Stage 9
Inivata Ltd Ongoing Clinical Trials by Trial Status 10
Inivata Ltd Ongoing Clinical Trials Summary 11
InVision ctDNA Assay - EGFR-Mutant NSCLC - Product Status 12
InVision ctDNA Assay - EGFR-Mutant NSCLC - Product Description 12
InVision ctDNA Assay - Metastatic Breast Cancer - Product Status 13
InVision ctDNA Assay - Metastatic Breast Cancer - Product Description 13
InVision ctDNA Assay - NSCLC - Product Status 14
InVision ctDNA Assay - NSCLC - Product Description 14
InVision ctDNA Assay - NSCLC - Liquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation: LIBERTI 15
InVision ctDNA Assay - Pancreatic Cancer - Product Status 16
InVision ctDNA Assay - Pancreatic Cancer - Product Description 16
InVision ctDNA Assay - Stage III/IV NSCLC - Product Status 17
InVision ctDNA Assay - Stage III/IV NSCLC - Product Description 17
InVision First - Product Status 18
InVision First - Product Description 18
InVision First - Analytical Validation of a Next Generation Sequencing Liquid Biopsy Assay for High Sensitivity Broad Molecular Profiling 19
InVision First - Evaluation of Liquid Biopsies for Molecular Profiling in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) in the Relapse Treatment Setting 19
InVision First - Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared with Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients with Advanced Non-small Cell Lung Cancer 19
Inivata Ltd, Key Employees 21
Inivata Ltd, Subsidiaries 22
Glossary 31

List of Figures
Inivata Ltd Pipeline Products by Equipment Type 6
Inivata Ltd Pipeline Products by Development Stage 9
Inivata Ltd Ongoing Clinical Trials by Trial Status 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Inivata Ltd:企業の製品パイプライン分析2018(Inivata Ltd - Product Pipeline Analysis, 2018 Update)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆